Disruption of Autophagic Flux and Treatment with the PDPK1 Inhibitor GSK2334470 Synergistically Inhibit Renal Cell Carcinoma PathogenesisWeimin Zhou(Jiangxi Provincial Cancer Hospital), Xinhua Tu(Jiangxi Provincial Cancer Hospital)Journal of CancerJanuary 1, 202410.7150/jca.92521Cited by 4SaveCiteExport RISWatch citationsRelated PapersFirst-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial|The Lancet Oncology|2025|10